Table 2.
Patient-, tumour- and treatment-related characteristics
| Patients (n) | % | Patients (n) | % | ||
|---|---|---|---|---|---|
| Age (years) | Hormone receptor status | ||||
| ≤40 | 0 | 0 | ER | ||
| 41–50 | 7 | 10 | Unknown | 1 | 1 |
| 51–60 | 8 | 12 | Positive (Allred >2) | 60 | 88 |
| >60 | 53 | 78 | Negative | 7 | 10 |
| WHO status | PR | ||||
| Unknown | 18 | 26 | Unknown | 1 | 1 |
| 0 | 34 | 50 | Positive (Allred >2) | 50 | 74 |
| 1 | 14 | 21 | Negative | 17 | 25 |
| ≥2 | 2 | 3 | |||
| Tumour size (mm) | |||||
| Unknown | 5 | 7 | Her2 | ||
| <5 | 9 | 13 | Unknown | 3 | 4 |
| 6–10 | 18 | 27 | 0 | 10 | 15 |
| 11–20 | 26 | 38 | 1+ | 31 | 46 |
| 21–50 | 10 | 15 | 2+ | 18 | 26 |
| >50 | 0 | 0 | 3+ | 6 | 9 |
| Nodal assessment | |||||
| Histological type | |||||
| IDC | 47 | 69 | Unknown | 1 | 1 |
| ILC | 11 | 16 | Sentinel node biopsy | 62 | 91 |
| IDC/ILC | 1 | 1 | Axillary node dissection | 1 | 1 |
| DCIS | 4 | 6 | None (DCIS) | 4 | 6 |
| Other | 5 | 7 | |||
| Number of positive nodes | |||||
| Histological grade | Unknown | 2 | 3 | ||
| Unknown | 1 | 1 | 0 | 59 | 87 |
| 1 | 22 | 32 | 1–3 | 7 | 10 |
| 2 | 31 | 46 | 4+ | 0 | 0 |
| 3 | 14 | 21 | |||
| Radiation treatment | |||||
| Presence of LVI | Tumour bed boost | 43 | 63 | ||
| Unknown | 2 | 3 | Regional lymph node irradiation | 4 | 6 |
| Yes | 0 | 0 | |||
| No | 66 | 97 | Adjuvant therapy | ||
| Endocrine therapy | 62 | 91 | |||
| Presence of PNI | Chemotherapy | 3 | 4 | ||
| Unknown | 2 | 3 | No adjuvant therapy | 3 | 4 |
| Yes | 1 | 1 | |||
| No | 65 | 96 | |||
| Tumour focality | |||||
| Unifocal | 64 | 94 | |||
| Multifocal | 4 | 6 | |||
DCIS, ductal carcinoma in situ; ER, oestrogen receptor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LVI, lymphovascular invasion; PNI, perineural Invasion; PR, progesterone receptor.